Develops immunotherapies based on its proprietary arenavirus platform, focusing on treating infectious diseases and cancer through innovative vaccine and immunotherapy approaches.
HOOKIPA Pharma Inc., headquartered in New York, New York, is a dynamic clinical stage biopharmaceutical company focused on advancing immunotherapeutics targeting both infectious diseases and cancers. Leveraging its proprietary arenavirus platform, HOOKIPA develops innovative treatments designed to harness the immune system's potential in combating these challenging conditions. The company's lead infectious disease candidate, HB-101, is currently undergoing a randomized double-blinded Phase II clinical trial. This treatment is aimed at patients awaiting kidney transplantation from cytomegalovirus-positive donors, addressing a critical medical need.
In oncology, HOOKIPA Pharma's forefront includes HB-201 and HB-202, lead product candidates undergoing Phase I/II trials. These therapies target human papillomavirus 16-positive cancers, illustrating the company's commitment to addressing specific oncogenic strains with significant unmet medical needs. Additionally, HOOKIPA's preclinical pipeline features promising programs such as HB-300 for prostate cancer and HB-700, which targets mutated KRAS in pancreatic, colorectal, and lung cancers. These initiatives highlight HOOKIPA's broad approach in developing next-generation immunotherapies with potential transformative impact.
Collaboration plays a pivotal role in HOOKIPA Pharma's strategy, exemplified by its partnership with Gilead Sciences, Inc. This collaboration focuses on exploring preclinical research programs aimed at developing innovative vaccine products utilizing HOOKIPA's replicating and non-replicating technology platforms for Hepatitis B Virus treatment, cure, diagnosis, or prevention. With its foundation in cutting-edge science and a commitment to addressing global health challenges, HOOKIPA Pharma Inc. continues to drive forward in its mission to deliver groundbreaking therapies to patients worldwide.